Therapeutic monoclonal antibodies (mAbs) such as rituximab (RTX, anti-CD20 for B-cell lymphomas) and trastuzumab (anti-HER2 for breast cancer) have revolutionized treatment for various types of cancers. Here, ERBB2 is linked to breast cancer.